Molbio Diagnostics IPO Oversubscribed 70x, Lists Monday
Scientist analyzes data from a compact diagnostic device in a modern lab
Key Highlights
Molbio Diagnostics IPO oversubscribed 70.26x, debuts August 17 on NSE & BSE. Experts predict a 14-16% listing premium. Learn more about the stock debut.
Molbio Diagnostics is set to list its on Monday, August 17, on both the and . The offering saw significant demand, oversubscribing by 70.26 times overall.
Snapshot
(QIBs) led the demand during the subscription period, which ran from August 10 to August 12.
- QIBs: 186.39 times
- Non-Institutional Investors (NIIs): 49.80 times
- investors: 12.96 times
Listing Outlook
The grey market premium () for Molbio Diagnostics IPO currently stands at ₹125. This suggests a potential listing price of ₹932, marking a 15.49% premium over the ₹807 issue price.
Market experts are forecasting a listing premium between 14-16%. Mahesh M Ojha of Kantilal Chhaganlal Securities advises long-term investors to hold the stock, citing promising growth prospects.
Harshal Dasani, Business Head at INVasset PMS, noted that the company’s post-listing performance hinges on its ability to sustain growth, increase recurring test-kit revenues, and expand internationally.
IPO Details & Utilization
The IPO’s price band was set between ₹768 and ₹807 per share. The issue comprised a fresh issue of shares worth ₹200 crore and an (OFS) of 91.66 lakh shares, totaling ₹739.70 crore.
Funds from the fresh issue are earmarked for strategic investments and expansion.
- Establishing an R&D facility and center of excellence via subsidiary Bigtec.
- Capital expenditure on new office spaces.
- Acquiring equipment for units in Goa and Visakhapatnam.
Company Profile
Molbio Diagnostics specializes in point-of-care (POC) diagnostics, focusing on accessible, rapid, and affordable healthcare technologies. The company has shown consistent revenue growth, from ₹836.56 crore in FY24 to ₹1,445.69 crore in FY26.